Take a
self-assessment
survey.
Subscribe to
be notified about
added CME
activities or site
improvements.
Reading List
Screening Tools
Screening for
Sleep Disorders, a Webcast for PCPs
in your patients.
Sleep University published a supplement to The Journal of Family Practice in April of 2008. The supplement is designed to provide practical information on collaborative patient care for family practitioners. Family physicians will receive protocols for better diagnosis and treatment of their patients with insomnia.
Please review the following Faculty information, and then select Step 3 to start the Activity.
Faculty
Larry Culpepper, MD, MPH
Professor and Chairman, Department of Family Medicine
Boston University School of Medicine
Chief, Department of Family Medicine
Boston University Medical Center
Boston, MA
Paul Doghramji, MD
Family Physician
Collegeville Family Practice
Collegeville, PA
Susan G. Kornstein, MD
Professor of Psychiatry and Obstetrics and Gynecology
Executive Director, Institute for Women's Health
Executive Director, Mood Disorders Institute
Virginia Commonwealth University
Richmond, VA
Thomas Roth, PhD
Division Head
Sleep Disorders Center
Henry Ford Hospital
Detroit, MI
Faculty Disclosures
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship that a faculty member or provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.
Dr. Culpepper has disclosed the following financial relationships:
Consultant – Neurocrine, Takeda, Pfizer, Wyeth, Forest, Eli Lilly
Speaker's Bureau – Pfizer, Wyeth, Forest
Dr. Doghramji has disclosed the following financial relationships:
Consultant – Cephalon, Neurocrine, Sanofi-Aventis, Takeda
Speaker's Bureau – Cephalon, Sanofi-Aventis, Sepracor, Takeda
Dr. Kornstein has disclosed the following financial relationships:
Consultant – Biovail Laboratories, Berlex, Bristol-Myers Squibb, Forest, Eli Lilly, Neurocrine, Pfizer, Sepracor, Wyeth
Grant/Research Support – Astra-Zeneca, Biovail Laboratories, Berlex, Boehringer-Ingelheim, Bristol-Myers Squibb, Department of Health and Human Services, Forest, GlaxoSmithKline, Merck, Mitsubishi-Tokyo Pharmaceuticals, Novartis, Pfizer, Sanofi-Synthelabo, Sepracor, Wyeth
Dr. Roth has disclosed the following financial relationships:
Consultant – Abbott, Acadia, Acoglix, Actelion, Alchemers, Alza, Ancil, Arena, AstraZeneca, Aventis, Bristol-Myers Squibb, Cephalon, Cypress, Dove, Elan, Eli Lilly, Evotec, Forest, GlaxoSmithKline, Hypnion, Johnson & Johnson, King, Lundbeck, Ortho-McNeil, MediciNova, Merck, Neurim, Neurocrine Biosciences, Neurogen, Novartis, Orexo, Organon, Orginer, Pfizer, Prestwick, Proctor & Gamble, Purdue, Resteva, Roche, Sanofi, Schering-Plough, Sepracor, Servier, Shire, Somaxon, Syrex, Takeda, TransOral
Speaker's Bureau – Sanofi, Takeda
Grant/Research Support – Aventis, Cephalon, GlaxoSmithKline, Neurocrine, Pfizer, Sanofi, Schering-Plough, Sepracor, Somaxon, Syrex, Takeda, TransOral, Wyeth, Xenoport
Drs. Culpepper, Doghramji, Kornstein, and Roth have indicated that their presentation will include information on the following off-label products: diphenhydramine, hydroxyzine, doxylamine, trazodone, doxepin, phenobarbital, quetiapine, olanzapine, melatonin, valerian, and L-tryptophan.
Adobe® Reader® is required for viewing this journal.